Aminolevulinic acid - Medac

Drug Profile

Aminolevulinic acid - Medac

Alternative Names: 5-ALA - Medac; 5-ALA - Photonamic; 5-ALA Patch; Alacare; Aminolevulinic acid HCl; Effala; Gleolan; Gliolan; PD P 506 A; PD P 506 A-PDT

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Photonamic
  • Developer LINK Healthcare; Medac; NX Development Corp; Photonamic; Specialised Therapeutics Australia; Spirig Pharma
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Actinic keratosis; Glioma
  • Phase II Onychomycosis

Most Recent Events

  • 30 Apr 2018 NX Development Corp has been acquired by Photonamic
  • 23 Aug 2017 Photonamic completes a phase II trial in Onychomycosis in Germany (Topical) (EudraCT2014-001493-34) (NCT02355899)
  • 08 Jun 2017 Registered for Glioma (Diagnosis) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top